Skip to main content

Clinical trial CANFOUR

An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors

Cancers
Organ Multiple
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor Cantargia AB
EudraCT Identifier 2017-001111-36
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03267316
Inclusion criteria Metastatic
Last update